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A B S T R A C T
Purpose: To evaluate the effectiveness and tolerability of zonisamide in children with epilepsy.
Method: Retrospective case note review of young people (less than 19 years) with epilepsy from three
UK tertiary centres who received treatment with zonisamide and were followed up for a minimum of 12
months.
Results: Fifty-seven children were included, aged 1.5–18.5 (median, 12) years. Thirty-three (57.9%)
patients had generalised epilepsy, 21 (36.8%) focal epilepsy, and three (5.3%) a mixed, generalised and
focal, epilepsy. Fifty-six of the 57 patients had been refractory to at least three previous antiepileptic
drugs. The maintenance dose of zonisamide was [range (median)] 0.7–14 (5) mg/kg/day. The median
duration of treatment for all patients was 12 (range 0.25–35) months. After 2 months of treatment, 51
patients remained on zonisamide, 18 (35.3%) of whom demonstrated a 50% reduction in seizure
frequency. At the end of the follow-up period, there was a loss of effect for some patients. Thirteen
(25.5%) of the 51 patients continued to demonstrate a 50% reduction in seizure frequency whilst two
who had become seizure-free started having seizures again. Six (11.8%) had<50% reduction, twenty-four
(47%) had no change, and eight (15.7%) had increasing seizures. Twenty-ﬁve (43.9%) patients reported
unwanted effects although this contributed to thewithdrawal of zonisamide in only ten (17.6%) patients.
Conclusions: Zonisamide appeared to be a reasonably effective and generallywell-tolerated antiepileptic
drug in a heterogeneous group of 57 children with poorly controlled epilepsy and provides another
treatment option for children with refractory seizures.
 2009 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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Zonisamide is a relatively new antiepileptic drug (AED) that has
been shown in animal models to have multiple mechanisms of
action,which in part explains its efﬁcacy in a broad range of seizure
types.1 These include blocking sustained repetitive action poten-
tials of voltage-gated sodium channels,2 reducing T-type calcium
channel current3 and modulating neurotransmitter systems such
as GABAergic and glutamate systems.4 It has favourable pharma-
cokinetic properties5 and few drug interactions.6–9
Zonisamide has beneﬁted from extensive clinical experience. In
Japan, it has been approved since 1989 for the adjunctive
treatment or monotherapy of partial or generalised seizures in
adults and children over 1 year old.10,11 Approval in the United
States in 2000 was speciﬁcally for adjunctive therapy of partial* Corresponding author. Tel.: +44 1512525163; fax: +44 1512525678.
E-mail address: rachel.kneen@alderhey.nhs.uk (R. Kneen).
1059-1311/$ – see front matter  2009 British Epilepsy Association. Published by Else
doi:10.1016/j.seizure.2009.10.008seizures in adults. The same label was extended to Europe in 2005
after four randomised, placebo-controlled studies showed efﬁcacy
in treating refractory partial seizures in adults.12–15
There are no published randomised clinical trials (RCT) of
zonisamide use in children. There are several open-label adjunc-
tive or ‘add-on’ studies reporting on children with mostly
refractory seizures.10,11,16–21 The responder rates, deﬁned as a
reduction in seizure frequency of at least 50%, range from 15% to
48.7%10,16–20 but the time that these responses have been
evaluated has not been standardised. Retention rates have been
reported as 54.2% at 1 year,18 48%21 to 74.4%20 at 15 months, and
41.7% at 18 months.19 At ﬁrst glance, the drug appears to be as
effective as other newer AEDs including lamotrigine (45%
responder rate)22 and topiramate (39% responder rate).22 How-
ever, these latter ﬁgures are derived from placebo-controlled RCTs
and comparisons regarding relative efﬁcacy cannot be made.
Several studies have also reported the use of zonisamide in
children as monotherapy or polytherapy in speciﬁc epilepsy
syndromes. Responder rates for zonisamide monotherapy in avier Ltd. All rights reserved.
Table 1
Demographic characteristics of 57 children treated with zonisamide.
N (%)
Age: median (range) 12 (1.5–18.5)
Sex: male/female 25 (43.9%)/32 (56.1%)
Seizure type and aetiology (%)
Generalised epilepsies 33 (57.9%)
Idiopathic (juvenile absence epilepsy) 1 (1.8%)
Cryptogenic 20 (35.1%)
Symptomatic 12 (21%)
Tuberous sclerosis 3 (5.3%)
Rett syndrome 3 (5.3%)
Malformation of cortical development 3 (5.3%)
Perinatal hypoxic ischaemic encephalopathy 1 (1.8%)
Acute disseminated encephalomyelitis 1 (1.8%)
SCN1a mutation 1 (1.8%)
Focal epilepsies 21 (36.8%)
Cryptogenic 9 (15.8%)
Symptomatic 12 (21%)
Focal cortical dysplasia 6 (10.5%)
Chromosomal 2 (3.5%)
Tuberous sclerosis 1 (1.8%)
Intracranial haemorrhage 1 (1.8%)
Perinatal hypoxic ischaemic encephalopathy 1 (1.8%)
Migrating partial seizures of infancy 1 (1.8%)
Mixed (generalised and focal) epilepsies 3 (5.3%)
Cryptogenic 1 (1.8%)
Symptomatic 2 (3.5%)
Worster–Drought syndrome 1 (1.8%)
Severe myoclonic epilepsy of infancy 1 (1.8%)
Learning difﬁculties
None 3 (5.3%)
Mild 4 (7%)
Moderate 15 (26.3%)
Severe 35 (61.4%)
Table 2
Initial concomitant antiepileptic drugs in 57 children treated with zonisamide.
Antiepileptic drugs Patients, n (%)
Lamotrigine 17 (29.8)
Levetiracetam 17 (29.8)
Valproate 17 (29.8)
Topiramate 13 (22.8)
Clonazepam 8 (14)
Ethosuximide 8 (14)
Carbamazepine 6 (10.5)
Clobazam 6 (10.5)
Phenobarbitone 5 (8.8)
Phenytoin 4 (7)
Oxcarbazepine 3 (5.3)
Others 9 (15.8)
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reports of zonisamide in infantile spasms (20–36% spasm-
free),10,11,25 juvenile myoclonic epilepsy (80% responder rate),26
absence seizures (51.1% seizure-free),27 and Lennox–Gastaut
syndrome (35–51.6% responder rate)11,28 demonstrate its efﬁcacy
in a wide range of epilepsy types.
This retrospective study describes the effectiveness and
tolerability of zonisamide in the treatment of children with
refractory epilepsy from three paediatric tertiary centres in the UK.
2. Methods
This was a retrospective study of zonisamide use in children
with epilepsy from three paediatric neurology regional centres in
the UK: RoyalManchester Children’s Hospital, Alder Hey Children’s
NHS Foundation Trust (Liverpool) and Royal Preston Hospital.
Patients who had been given a prescription for zonisamide
between September 2004 and January 2008 were identiﬁed from
hospital and pharmacy records. Medical records were reviewed
and clinical information was recorded on a standard proforma.
Where possible, seizure types and epilepsy syndromes were
classiﬁed using clinical, EEG and neuroimaging data. Case notes
were reviewed and data was extracted for all patients who had
been followed up for a minimum period of 12 months since
starting zonisamide. The study was registered with the Trusts’
audit departments. All notes were handled in accordance with
national guidelines. Ethical approval was not required.
For the purposes of this study, the effectiveness of zonisamide
was evaluated by comparing changes in seizure frequency from
seizure diaries/data completed by caregivers. The baseline seizure
frequency was obtained from the clinic letter written at the time
zonisamide was ﬁrst prescribed. A judgement on the relative
change in seizure frequency was inferred from subsequent clinic
letters, and was documented as follows: seizure-free, 50%
reduction seizure frequency, <50% reduction frequency, no
change, or increased seizures. Response rates were assessed at
the following times: 2 months after starting zonisamide, at the
time a decision was made to withdraw zonisamide and at the last
recorded follow-up appointment for those who continued on
zonisamide. Initial responders were deﬁned as those patients who
achieved a 50% decrease in seizure frequency at 2 months
following the introduction of the drug.
Tolerability was assessed by recording any documented
unwanted effects. Treatment retention (percentage of patients
remaining on zonisamide) is considered a good indicator of
effectiveness and tolerability and this was reported 12 months
after the commencement of zonisamide.
Data analysis was descriptive. Selected categorical variables
were compared using Chi-square analysis and continuous vari-
ables using independent t-test.
3. Results
3.1. Patient characteristics
Fifty-seven children were identiﬁed and evaluated (32 females
and 25 males). The median age at the time of initiation of
zonisamide treatment was 12 years (range 1.5–18.5 years).
Patients were classiﬁed according to seizure type (generalised,
focal, mixed), aetiology (idiopathic, cryptogenic or symptomatic),
and epilepsy syndrome. Fifty-six of the 57 patients had failed to
achieve acceptable seizure control on aminimumof three previous
AEDs (median 8: range 2–16). Four patients had undergone
epilepsy surgery (corpus callostomy in two, and one each, parietal
and temporal lobectomies and hemispherectomy). Eight had
undergone insertion of a vagal nerve stimulator (VNS) prior totreatment with zonisamide and stimulation was continued in all
eight patients throughout the study. Most patients had moderate
to severe learning difﬁculties. A summary of patients’ character-
istics and a breakdown of seizure types and aetiology are presented
in Table 1.
3.2. Zonisamide treatment and concomitant antiepileptic drugs
Zonisamide was initiated as adjunctive therapy in all 57
patients. During the course of treatment, three patients had their
concomitant AEDs withdrawn and received zonisamide as mono-
therapy. The median (range) duration of zonisamide treatment
was 12 (0.25–35) months. The median (range) ﬁnal maintenance
dose was 5 (0.7–14) mg/kg/day. The median (range) number of
concomitant AEDs usedwas 2 (1–4) with themost commonly used
ones being lamotrigine, levetiracetam, sodium valproate, and
topiramate (Table 2). Patients on VNS therapy did not have many
adjustments to the VNS settings during the study.
Fig. 2. Effectiveness by aetiology.
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Six patients stopped taking zonisamide before 2months: in two
no reason was documented, in two there were intolerable
unwanted effects (allergic rash in one, and a combination of
tiredness, anorexia and emotional lability in one) and in the
remaining two, the seizure frequency had increased. We excluded
these six patients from analysis, as their period on treatment was
considered insufﬁcient to adequately assess the drug’s effective-
ness.
Of the remaining 51 children, 18 (35.3%) were designated as
‘initial responders’ 2months after treatmentwas commenced. This
effectiveness was subsequently lost in ﬁve of these 18 patients
between 4 and 8 months of treatment. During this time, one or
more of the concomitant AEDs had beenwithdrawn in three of ﬁve
children. Seizures deteriorated in one patient following a reduction
in the dose of zonisamide because of side-effects.
The median (range) length of follow-up for the 51 patients who
remained on zonisamide was 12 (2–35) months. Thirteen (25.5%)
of the 51 patients continued to demonstrate a reduction in seizure
frequency of 50%. Six (11.8%) patients were classiﬁed as having a
<50% reduction in seizure frequency or some improvement in their
epilepsy. Twenty-four (47%) patients showed no change in their
seizure frequency, and eight (15.7%) had increased seizures.
Two children became seizure-free during treatment with
zonisamide but the effects of the drug diminished with time.
One with symptomatic focal epilepsy, secondary to focal (frontal)
cortical dysplasia, became seizure-free for 18 months but then
experienced a recurrence of infrequent focal sensory auras which
did not progress. One patient with Lennox–Gastaut syndrome,
with a pre-treatment daily seizure frequency of 150 brief tonic
seizures was initially seizure-free for the ﬁrst 5 months but then
developed breakthrough tonic seizures, coinciding with the
withdrawal of a concomitant AED. Both patients continued with
zonisamide treatment as it still produced a>50% reduction in their
seizure frequency.
Analysis of effectiveness by seizure type and aetiology was
undertaken in 51 patients (Figs. 1 and 2). Four (23.5%) of 17
patients with focal, eight (25%) of 32 patients with generalised, and
one (50%) of two patients with ‘mixed’ epilepsy demonstrated a
50% reduction in seizure frequency. The difference was not
statistically signiﬁcant (p > 0.5). Four (18%) of 22 patients with
symptomatic and nine (31%) of 29 with cryptogenic epilepsyFig. 1. Effectiveness by seizure type.showed a 50% reduction in seizure frequency. This did not reach
statistical signiﬁcance (p > 0.5). Nine children had drug-resistant
infantile or epileptic spasms in isolation or in combination with
other seizure types. Three (33.3%) of these nine demonstrated a
reduction in spasms of50%. Eight had Lennox–Gastaut syndrome
but only one (12.5%) patient had a 50% reduction in seizure
frequency.
Three patients had gradual withdrawal of all their concomitant
AEDs and subsequently received zonisamide as monotherapy. One
with symptomatic focal epilepsy discontinued zonisamide after 3
months as there was no improvement in seizure control and was
then treated with sodium valproate. The remaining two children
with cryptogenic generalised and cryptogenic focal epilepsy had a
reduction in seizure frequency of 50% at doses of 7.5 and 8.8 mg/
kg/day. They continuedwith zonisamide asmonotherapy although
one of these children had worsening behaviour which may or may
not have been treatment-related.
4. Retention and tolerability
Thirty-one (54.4%) of the 57 patients remained on zonisamide
treatment 1 year after it was started. At the end of the study period,
30 (52.7%) had discontinued treatment: 13 (22.8%) because of lack
of therapeutic beneﬁt, ﬁve (8.8%) because of unwanted effects, ﬁve
(8.8%) because of an increase in seizure frequency, ﬁve (8.8%)
because of a combination of increase in seizure frequency and
unwanted effects, and two (3.5%) following parents’ requests (no
reason documented). Two patients died from respiratory compli-
cations, one with Ohtahara syndrome and one with cryptogenic
infantile epileptic encephalopathy; they had received zonisamide
for 26 and 24 months, respectively.
Twenty-ﬁve (43.9%) of the 57 patients reported at least one
unwanted effect after commencing zonisamide (Table 3). Themost
frequently reported were anorexia (12.3%), fatigue (12.3%),
agitation or irritability (10.5%), and somnolence (8.8%). Most
patients had mild to moderate unwanted effects which resolved
spontaneously or after an adjustment of the dose of zonisamide.
Of the ten children who stopped zonisamide because of
unwanted effects, two developed psychotic symptoms manifest
by aggressiveness and visual hallucinations 2.5 and 12 months
after starting treatment. The doses of zonisamide for these children
were 4 and 2.8 mg/kg/day, respectively. One of these patients had
experienced similar episodes prior to the use of zonisamide.
Symptoms resolved in both patients after withdrawal of the drug.
In the remaining eight patients, the unwanted effects that
contributed to the decision to withdraw zonisamide included:
fatigue, anorexia, weight loss, abdominal pain (1); diarrhoea and
Table 3
Unwanted effects (n=57).
Unwanted effects n (%)
Anorexia 7 (12.3)
Fatigue 7 (12.3)
Agitation/irritability 6 (10.5)
Somnolence 5 (8.8)
Mood lability 4 (7)
Weight loss 3 (5.3)
Aggression 3 (5.3)
Psychosis 2 (3.5)
Abdominal pain 2 (3.5)
Cognitive dysfunction 2 (3.5)
Diarrhoea 2 (3.5)
Sleep disturbance 1 (1.8)
Cool peripheries 1 (1.8)
Rash and hypersensitivity 1 (1.8)
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function tests (1); fatigue, anorexia and emotional lability (1);
anorexia and somnolence (1); drowsiness (1); lethargy (1);
irritability (1).
5. Discussion
Zonisamide has been prescribed in Japan for the last 20 years
but has only received a license for the adjunctive treatment of
partial seizures in adults in the UK in 2005. In addition, there are
few controlled trials of zonisamide in treating the paediatric
epilepsies. Consequently, most paediatric neurologists use new
AEDs off-license in childrenwho have chronic and previously drug-
resistant epilepsy. This report describes the use of zonisamide in a
heterogenous group of children with refractory epilepsy and as
such, it represents one of the largest reported experiences of this
anticonvulsant.
We have found that zonisamide is reasonably effective: 35.3% of
our patients were initial responders and 25.5% continued to
demonstrate this response at the time of last follow-up. Analysis by
seizure type showed that 23.5% with focal and 25% with
generalised seizures were classiﬁed as responders. Seizures were
reported to have increased in frequency in ten (17.6%) children,
with most (eight) occurring during the ﬁrst 3 months of treatment
with zonisamide. There was no obvious correlation between
response and either the aetiology of the epilepsy or seizure types.
Unwanted side-effects were common, occurring in almost half of
the children. However, these led to the discontinuation of
treatment in only ten (17.6%) children.
Initial data on the use of zonisamide in children originated from
Japan and has been summarised by Glauser and Pellock, and
Ohtahara.10,11 Four open-label trials assessed zonisamide as
adjunctive therapy in children with previously drug-resistant
epilepsy. The pooled results from these trials showed the responder
rate to be 34% (47/137) of thosewith partial-onset seizures and only
15% (8/54) of those with generalised-onset seizures.10,11 Five open-
label trials assessed zonisamide asmonotherapy in the treatment of
newly diagnosed and treatment-resistant epilepsywith a responder
rate of between 71 and 78%.10,11 One large, open-label, phase III trial
of 393 patients represents the only well-controlled trial of
zonisamide use in children to date and this demonstrated an overall
responder rate of 44.3%.29
Kim et al.17 recently evaluated zonisamide asmonotherapy and
adjunctive therapy in 68 children with predominantly refractory
epilepsy. Five were already in remission prior to commencing
zonisamide. They reported a responder rate of 46.8%. Another
study showed a responder rate of 42% 12months after treatment in
35 children with intractable epilepsy.18 Kluger et al.19 reported a
41.7% responder rate at the end of an 18-month follow-up on 24patients with highly refractory childhood-onset epilepsy followed
for at least 18 months. Finally, Coppola et al. observed a responder
rate in 48.7% of 82 children and young adults (aged 3–34 years)
with refractory epilepsy.20
Our study shows a lower responder rate than most of these
earlier studies. The reasons for this are likely to be multiple. These
include the fact that our study involved a high proportion of
children with generalised epilepsy (57.9%), compared to previous
studies where the proportion ranged from 12.5% to 43%.18–20
Earlier studies had indicated a lower response rate in patients with
a generalised epilepsy.10,11 Seven of our 33 with generalised
epilepsy had Lennox–Gastaut syndrome. Although pooled analysis
in Japan11 and a recent study in Korea28 found a responder rate of
35% and 51.6%, respectively, this remains an extremely difﬁcult
epilepsy syndrome to treat. An additional explanation is that the
majority of patients in the current study were children with highly
intractable epilepsy, asmanifest by themedian number of previous
(and ineffective) antiepileptic drugs and the number of patients
who had VNS. Zonisamide was one of few treatment options left to
consider in this highly refractory population.
There was a loss of effectiveness during the course of treatment
with zonisamide in ﬁve of the 18 initial responders, as well as both
the patients who had been seizure-free. Withdrawal of concomi-
tant AEDs and reduction of dose of zonisamide were factors in ﬁve
of these seven patients that may have contributed to the loss of
effect. There has been increasing evidence about the development
of tolerance to effect of most AEDs during prolonged treatment
and, although an infrequent cause, would be plausible especially in
such a refractory population.30
The doses of zonisamide used in the current study (0.7–14 mg/
kg/day) were comparable to those used in other studies with the
lower maintenance doses quoted as being between 0.7 and 4 mg/
kg/day and the higher doses between 8 and up to 35 mg/kg/
day.10,16–21 The median dose of zonisamide in our responders was
higher (6.2 mg/kg/day) when compared to the rest of the group
(4.5 mg/kg/day), but this differencewas not statistically signiﬁcant
(p > 0.05). Other studies18,23 have found the converse to be true,
i.e. the dose in responders was lower than in non-responders,
suggesting that further increases in dose may not be justiﬁed if no
response is seen atmoderate doses. In addition, themedian dose of
zonisamide in the 25 children who reported unwanted effects was
lower (4.4 mg/kg/day), when compared to those who did not
report any side-effects (6.35 mg/kg/day). This has been reported
previously and it was suggested that it was due to different rates of
clearance or an idiosyncratic response to the medication.18
The incidence of unwanted effects (43.9%) was lower than in
other published series (46–71.4%).16–19,21 One reason for this may
the high proportion of children with severe learning difﬁculties
who may not have been able to describe unwanted effects. It has
been reported that behavioural and psychiatric effects with the
group of AEDs classiﬁed as modulators of voltage-gated cationic
channels (which includes zonisamide) are infrequent in compar-
ison with other groups of antiepileptics.31 However, a high
incidence of psychotic symptoms with zonisamide use was noted
in two Japanese studies, one involving children (6%) and reported
in the paper by Glauser and Pellock10 and the other involving adult
and paediatric patients (18.9%).32 Kanner33 summarised ﬁndings
from several studies suggesting that psychiatric events during
treatment with a number of AEDs occur more frequently in
patients at risk of psychiatric disorders. In our study, the two
children with psychosis had susceptible neuropsychiatric proﬁles;
one had a diagnosis of Landau–Kleffner syndrome and the other
had an unidentiﬁed encephalopathy with previous episodes of
agitation and confusion. It is unclear whether the recurrence of
these psychological symptoms was directly related to the use of
zonisamide.
H.J. Tan et al. / Seizure 19 (2010) 31–35 35Although this study is retrospective and subjective, it does
contribute to the existing knowledge and experience of the
effectiveness and safety of zonisamide in children. It provides data
that suggests that treatment with zonisamide may produce
sustained improvement in seizure control in some children with
previously drug-resistant epilepsy. There was no obvious correla-
tion between effectiveness and seizure type or aetiology.
Zonisamide does appear to offer an additional treatment option
for children with refractory epilepsy. However, it remains unclear
as to whether it is as effective as other AEDs including sodium
valproate, topiramate or lamotrigine. This can only be answered by
undertaking randomised controlled trials which compare zonisa-
mide with these other anticonvulsants.
Acknowledgements
The authors are grateful for the assistance and support from the
pharmacists, epilepsy nurses, neurophysiology departments and
administrative staff at their respective hospitals. They would also
like to thank Dr. P. Tomlin at Royal Preston Hospital and Dr. A.
Curran at Alder Hey Children’s hospital for providing relevant
patient details.
References
1. Baulac M. Introduction to zonisamide. Epilepsy Research 2006;68(Suppl. 2):S3–9.
2. Rock DM, Macdonald RL, Taylor CP. Blockade of sustained repetitive action
potentials in cultured spinal cord neurons by zonisamide (AD 810, CI 912), a
novel anticonvulsant. Epilepsy Research 1989;3(2):138–43.
3. Kito M, Maehara M, Watanabe K. Mechanisms of T-type calcium channel
blockade by zonisamide. Seizure 1996;5(2):115–9.
4. Ueda Y, Doi T, Tokumaru J, Willmore LJ. Effect of zonisamide on molecular
regulation of glutamate and GABA transporter proteins during epileptogenesis
in rats with hippocampal seizures. Brain Research Molecular Brain Research
2003;116(1–2):1–6.
5. Kochak GM, Page JG, Buchanan RA, Peters R, Padgett CS. Steady-state pharma-
cokinetics of zonisamide, an antiepileptic agent for treatment of refractory
complex partial seizures. Journal of Clinical Pharmacology 1998;38(2):166–71.
6. Levy RH, Ragueneau-Majlessi I, Garnett WR, Schmerler M, Rosenfeld W, Shah J,
et al. Lack of a clinically signiﬁcant effect of zonisamide on phenytoin steady-
state pharmacokinetics in patients with epilepsy. Journal of Clinical Pharmacol-
ogy 2004;44(11):1230–4.
7. Levy RH, Ragueneau-Majlessi I, Brodie MJ, Smith DF, Shah J, Pan WJ. Lack of
clinically signiﬁcant pharmacokinetic interactions between zonisamide and
lamotrigine at steady state in patients with epilepsy. Therapeutic Drug Monitor-
ing 2005;27(2):193–8.
8. Ragueneau-Majlessi I, Levy RH, Bergen D, Garnett W, Rosenfeld W, Mather G,
et al. Carbamazepine pharmacokinetics are not affected by zonisamide: in vitro
mechanistic study and in vivo clinical study in epileptic patients. Epilepsy
Research 2004;62(1):1–11.
9. Ragueneau-Majlessi I, Levy RH, Brodie M, Smith D, Shah J, Grundy JS. Lack of
pharmacokinetic interactions between steady-state zonisamide and valproic
acid in patients with epilepsy. Clinical Pharmacokinetics 2005;44(5):517–23.
10. Glauser TA, Pellock JM. Zonisamide in pediatric epilepsy: review of the Japanese
experience. Journal of Child Neurology 2002;17(2):87–96.
11. Ohtahara S. Zonisamide in the management of epilepsy—Japanese experience.
Epilepsy Research 2006;68(Suppl. 2):S25–33.12. Schmidt D, Jacob R, Loiseau P, Deisenhammer E, Klinger D, Despland A, et al.
Zonisamide for add-on treatment of refractory partial epilepsy: a European
double-blind trial. Epilepsy Research 1993;15(1):67–73.
13. Faught E, Ayala R, Montouris GG, Leppik IE. Randomized controlled trial of
zonisamide for the treatment of refractory partial-onset seizures. Neurology
2001;57(10):1774–9.
14. Sackellares JC, Ramsay RE, Wilder BJ, Browne 3rd TR, Shellenberger MK.
Randomized, controlled clinical trial of zonisamide as adjunctive treatment
for refractory partial seizures. Epilepsia 2004;45(6):610–7.
15. Brodie MJ, Duncan R, Vespignani H, Solyom A, Bitenskyy V, Lucas C. Dose-
dependent safety and efﬁcacy of zonisamide: a randomized, double-blind,
placebo-controlled study in patients with refractory partial seizures. Epilepsia
2005;46(1):31–41.
16. Santos CC, Brotherton T. Use of zonisamide in pediatric patients. Pediatric
Neurology 2005;33(1):12–4.
17. Kim HL, Aldridge J, Rho JM. Clinical experience with zonisamide monotherapy
and adjunctive therapy in children with epilepsy at a tertiary care referral
center. Journal of Child Neurology 2005;20(3):212–9.
18. Mandelbaum DE, Bunch M, Kugler SL, Venkatasubramanian A, Wollack JB.
Broad-spectrum efﬁcacy of zonisamide at 12 months in children with intract-
able epilepsy. Journal of Child Neurology 2005;20(7):594–7.
19. Kluger G, Zsoter A, Holthausen H. Long-term use of zonisamide in refractory
childhood-onset epilepsy. European Journal of Paediatric Neurology 2008;12(1):
19–23.
20. Coppola G, Grosso S, Verrotti A, Parisi P, Luchetti A, Franzoni E, et al. Zonisamide
in children and young adults with refractory epilepsy: an open label, multi-
center Italian study. Epilepsy Research 2009;83(2–3):112–6.
21. Shinnar S, Pellock JM, Conry JA. Open-label, long-term safety study of zonisa-
mide administered to children and adolescents with epilepsy. European Journal
of Paediatric Neurology 2009;13(1):3–9.
22. French JA, Kanner AM, Bautista J, Abou-Khalil B, Browne T, Harden CL, et al.
Efﬁcacy and tolerability of the new antiepileptic drugs, II: treatment of refrac-
tory epilepsy: report of the TTA and QSS Subcommittees of the American
Academy of Neurology and the American Epilepsy Society. Epilepsia
2004;45(5):410–23.
23. Kothare SV, Kaleyias J, Mostoﬁ N, Valencia I, Melvin JJ, Hobdell E, et al. Efﬁcacy
and safety of zonisamide monotherapy in a cohort of children with epilepsy.
Pediatric Neurology 2006;34(5):351–4.
24. Wilfong AA. Zonisamide monotherapy for epilepsy in children and young
adults. Pediatric Neurology 2005;32(2):77–80.
25. Lotze TE, Wilfong AA. Zonisamide treatment for symptomatic infantile spasms.
Neurology 2004;62(2):296–8.
26. Kothare SV, Valencia I, Khurana DS, Hardison H, Melvin JJ, Legido A. Efﬁcacy and
tolerability of zonisamide in juvenile myoclonic epilepsy. Epileptic Disorders
2004;6(4):267–70.
27. Wilfong A, Schultz R. Zonisamide for absence seizures. Epilepsy Research
2005;64(1–2):31–4.
28. You SJ, Kang HC, Kim HD, Lee HS, Ko TS. Clinical efﬁcacy of zonisamide in
Lennox–Gastaut syndrome: Koreanmulticentric experience. Brain Development
2008;30(4):287–90.
29. Oguni H, Hayshi K, Fukuyama Y, Watanabe K, Mimaki T, Ontanara. et al. Phase
III clinical study of the new antiepileptic drug AD-810 (zonisamide) in patients
with childhood epilepsy. Japanese Journal of Pediatrics 1988;41:439–50. [in
Japanese].
30. Loscher W, Schmidt D. Experimental and clinical evidence for loss of effect
(tolerance) during prolonged treatment with antiepileptic drugs. Epilepsia
2006;47(8):1253–84.
31. Glauser TA. Behavioral and psychiatric adverse events associated with anti-
epileptic drugs commonly used in pediatric patients. Journal of Child Neurology
2004;19(Suppl. 1):S25–38.
32. Miyamoto T, Kohsaka M, Koyama T. Psychotic episodes during zonisamide
treatment. Seizure 2000;9(1):65–70.
33. Kanner AM. Can antiepileptic drugs unmask a susceptibility to psychiatric
disorders? Nature Clinical Practice Neurology 2009;5(3):132–3.
